Business Wire

DC-DALBERG-ADVISORS

25.3.2024 06:01:31 CET | Business Wire | Press release

Share
Dalberg Awarded 5-Year Contract to Strengthen United States Agency for International Development's (USAID) Work With the Private Sector

Dalberg Advisors (https://Dalberg.com/) has announced the award of the Private Sector Engagement Strategic Collaboration and Leading-Edge Engagement (“PSE SCALE”) program, a framework agreement of advisory services that will support the U.S. Agency for International Development (USAID: https://www.USAID.gov/) to engage the private sector to achieve development and humanitarian outcomes. Through the five-year, $99.1-million contract, Dalberg and its partners will support USAID to accelerate private sector partnerships around the world and transform the Agency’s capacity to work with the private sector.

PSE SCALE is an extension of over 20 years of efforts by USAID to increasingly partner and invest with the private sector to achieve the Agency’s development and humanitarian goals. It represents the flagship mechanism to upgrade USAID’s capacity to work with the private sector and will provide a range of technical and advisory services to USAID Missions and operating units seeking to expand or accelerate private sector engagement. Activities include support for strategy development, organizational effectiveness, workforce development, partnership facilitation, market research and more. In an increasingly complex global environment, the objective of this work is to position USAID as a capable and vital partner to companies seeking to drive growth and innovation in new markets, reduce risk, and advance sustainability goals.

Dalberg and a consortium of partners— 60 Decibels (https://60Decibels.com/), CrossBoundary (https://CrossBoundary.com/), Vera Solutions (https://VeraSolutions.org/), and Social Solutions International (https://www.SocialSolutions.biz/)—will provide a comprehensive and integrated suite of services that are delivered on-demand and in response to needs and opportunities in any operating unit across USAID. The team collectively brings decades of experience in serving clients globally across the public and private sectors on a wide range of sustainable development issues.

“Dalberg is thrilled to be supporting USAID in deepening its collaboration with the private sector. Our experience and local networks across markets in Africa, Asia, and Latin America makes Dalberg a natural partner for USAID,” said Gaurav Gupta, Dalberg’s Global Managing Partner. “And with over 1,100 clients across the public and private sectors, we have a long track record of designing successful cross-sector partnerships that help all parties to advance their goals.”

Distributed by APO Group on behalf of Dalberg Advisors.

Download image: https://apo-opa.co/4cw4lVk (Illustration of multi-sectorial activities)

About Dalberg Advisors:

Dalberg Advisors is a strategic advisory firm that combines private sector strategy skills and analytical capabilities with deep knowledge and networks across emerging and frontier markets. Dalberg works actively across the public, private, and philanthropic sectors to help clients achieve their goals and has over 500 employees across 25 locations in Africa, Asia-Pacific, Latin America, Europe, and the U.S. Dalberg Advisors is part of the Dalberg Group, which comprises a collection of mission-driven enterprises—Dalberg Advisors, Dalberg Data Insights, Dalberg Design, Dalberg Media, Dalberg Implement, Dalberg Research—and the not-for-profit, Dalberg Catalyst.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240324686686/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye